Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene relationship to disease-free survival in breast cancer

Autor: Anne C. Carter, Zheng Tian Rhong, Dong S. Kim, A. Grossman, Joseph Feldman, William T. Thelmo, Karen B. Eisenberg, Peter Benn, Kamran Nayeri, Louis P. Pertschuk
Rok vydání: 1993
Předmět:
Zdroj: Cancer. 71:162-171
ISSN: 1097-0142
0008-543X
Popis: Background. It is important to develop parameters that aid in prognosticating which patients with breast cancer are more likely to have a rapid disease course and therefore might benefit from early aggressive therapies. Methods. Specimens from two groups of women, deliberately selected because their clinical courses differed greatly, were studied to detect amplification of the protooncogenes c-myc, int-2, and C-erbB-2/neu by slot-blot assay, the estrogen receptor (ER), and the progesterone receptor (PR) by both biochemical and immunohisto-chemical procedures (ERICA and PRICA). One group of 50 patients had a prolonged disease-free interval after initial surgery (mean, 6.4 years); the other group of 52 women had had rapid disease recurrence (mean, 1.4 years) or progression (5 patients died of disease within 1 year of diagnosis). The patients were selected from 1700 consecutively accessioned cases if they fit the study criteria and sufficient tissue was available for oncogene hybridization studies. Results. The two groups differed statistically by stage, number of involved axillary lymph nodes, ERICA and PRICA results (P = 0.001), and amplification of c-myc (P = 0.003). The percentage of patients with rapid disease recurrence and progression increased from 0–93% when risk factors changed from best case (ERICA and PRICA results, positive; c-myc, not amplified; and axillary nodes, not involved) to worst case (ERICA and PRICA findings, negative; c-myc, amplified; and axillary nodes, involved). Conclusions. Women with these worst-case parameters were more likely to have a recurrence sooner and rapidly progressive disease. They might benefit from early aggressive therapeutic measures. Cancer 1993; 71:162-71.
Databáze: OpenAIRE
Externí odkaz: